An early work, presented in 1995 by Dentico and colleagues, evaluated the effect of 30-day administration of high doses of intravenous or intramuscular GSH on liver cytolysis indexes in patients with chronic steatosic liver disease ( A subsequent study of Irie and colleagues in 2016 showed that the use of oral glutathione, at a daily dosage of 300 milligrams per day, may prevent NASH progression from NAFLD ( The study by Honda et al., conducted in 2017, was an open-label, single-arm, multicentre pilot study that evaluated the therapeutic effect of oral glutathione administration (300 mg/day) in patients with NAFLD through the evolution of biochemical indices (ALT) and liver fat levels assessed by VCTE ( These preliminary studies suggest a potential therapeutic effect of oral administration of GSH in NAFLD
Cagrilintide does not show a comparable heart-rate signal
The effect was dose-dependent within a specific range, with the most pronounced results between 10 to the negative twelfth and 10 to the negative ninth molar
doi: 10.1007/s12011-023-03782-1 81
Orita et al., 1983) and that diuretics, in general, appear to have adverse effects on renal (and muscular) glycolysis and gluconeogenesis, at least in rodents (Jones and Landon, 1967